RECRUITING

Efficacy of Repeated Low-level Red-light Therapy in Myopia Control

Talk to us

Conditions

Myopia

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Low-level red-light technology provides a new and innovative myopia control approach. This strategy enables relatively high energies of light to be delivered at much shorter durations of exposure to induce the myopia control effect. The efficacy of the low-level red-light technology has been proven in a Chinese population. This trial demonstrated that 3-minutes per session twice a day repeated low-level red-light treatment controlled 87.7% of refraction progression and 76.8% of axial length elongation when the time of compliance to the treatment was 75%. Repeating this RCT in culturally diverse groups will confirm and translate this technology into a solution for myopia control globally.

Official Title

Efficacy of Repeated Low-level Red-light Therapy in Myopia Control: a Randomized Controlled Trial

Quick Facts

Study Start:2023-07-14
Study Completion:2025-07-14
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05606237

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:8 Years to 13 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD
Inclusion CriteriaExclusion Criteria
  1. 1. Provision of consent
  2. 2. Age: ≥8 and ≤13 years at enrollment
  3. 3. Myopia: Spherical equivalent refractions (SERs) under cycloplegia: -1.00 to -5.00 diopters (D)
  4. 4. Astigmatism of 2.50 D or less
  5. 5. Anisometropia of 1.50 D or less
  6. 6. Corrected monocular logMAR visual acuity (VA): 1.0 or better
  7. 7. Consent to participate in random allocation of grouping
  8. 8. Fluent in English
  9. 9. Willing and able to participate in all required activities of the study
  10. 10. Race/ethnicity is either African, Hispanic, or Caucasian.
  1. 1. Strabismus and binocular vision abnormalities in either eye
  2. 2. Ocular abnormalities in either eye or other systemic abnormalities that affect participate in all required activities of the study.
  3. 3. Prior treatment of myopia control in either eye, including but not limited to drugs, orthokeratology, progressive addition lenses, bifocal lenses, etc.
  4. 4. Other reasons, including but not limited to severe physical and cognitive disability, that the physician may consider inappropriate for enrollment
  5. 5. Noncompliance with treatment
  6. 6. Children whose parents do not sign informed consent

Contacts and Locations

Study Contact

Julius Oatts, MD
CONTACT
(415) 353-2800
julius.oatts@ucsf.edu

Principal Investigator

Julius Oatts, MD
PRINCIPAL_INVESTIGATOR
University of California, San Francisco

Study Locations (Sites)

University of California, San Francisco
San Francisco, California, 94143
United States

Collaborators and Investigators

Sponsor: University of California, San Francisco

  • Julius Oatts, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-07-14
Study Completion Date2025-07-14

Study Record Updates

Study Start Date2023-07-14
Study Completion Date2025-07-14

Terms related to this study

Keywords Provided by Researchers

  • myopia

Additional Relevant MeSH Terms

  • Myopia